IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Dearborn Partners LLC

Dearborn Partners LLC trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.5% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 1,080 shares of the company’s stock after selling 75 shares during the period. Dearborn Partners LLC’s holdings in IDEXX Laboratories were worth $447,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Cranbrook Wealth Management LLC increased its stake in IDEXX Laboratories by 7.0% during the fourth quarter. Cranbrook Wealth Management LLC now owns 382 shares of the company’s stock worth $158,000 after acquiring an additional 25 shares during the last quarter. Perigon Wealth Management LLC lifted its position in IDEXX Laboratories by 1.8% during the fourth quarter. Perigon Wealth Management LLC now owns 1,474 shares of the company’s stock valued at $632,000 after buying an additional 26 shares in the last quarter. Summit Trail Advisors LLC grew its stake in IDEXX Laboratories by 3.3% during the fourth quarter. Summit Trail Advisors LLC now owns 810 shares of the company’s stock worth $335,000 after buying an additional 26 shares during the period. First Horizon Advisors Inc. increased its position in shares of IDEXX Laboratories by 4.0% in the third quarter. First Horizon Advisors Inc. now owns 704 shares of the company’s stock worth $356,000 after acquiring an additional 27 shares in the last quarter. Finally, Brown Brothers Harriman & Co. raised its stake in shares of IDEXX Laboratories by 4.4% in the 3rd quarter. Brown Brothers Harriman & Co. now owns 743 shares of the company’s stock valued at $375,000 after acquiring an additional 31 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In other news, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the completion of the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. The trade was a 49.50 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP George Fennell sold 9,986 shares of the firm’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now owns 8,176 shares in the company, valued at approximately $3,781,645.28. This represents a 54.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 2.18% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on IDXX shares. Bank of America upped their price target on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research report on Tuesday, February 4th. Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Morgan Stanley reduced their price target on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a research report on Tuesday, February 4th. Finally, Piper Sandler boosted their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research report on Monday, February 10th. Four equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Stock Performance

Shares of IDXX opened at $426.69 on Wednesday. The stock has a market capitalization of $34.70 billion, a PE ratio of 39.99, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The business’s fifty day moving average price is $438.11 and its 200 day moving average price is $448.27. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.31 and a quick ratio of 0.95. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $552.20.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.